Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TLSA
stocks logo

TLSA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Valuation Metrics

The current forward P/E ratio for Tiziana Life Sciences Ltd (TLSA.O) is -8.95, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Tiziana Life Sciences Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.55
Current PE
-8.95
Overvalued PE
-2.88
Undervalued PE
-8.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TLSA News & Events

Events Timeline

(ET)
2025-12-12
14:20:00
Tiziana Life Sciences Begins Early Alzheimer's Clinical Trial
select
2025-12-02 (ET)
2025-12-02
07:11:00
Tiziana Life Sciences to Spin Out TZLS-501 into Publicly Traded Company
select
2025-11-25 (ET)
2025-11-25
08:36:27
Tiziana Life's foralumab Phase 2 study approved for inclusion in the Healey ALS program
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
04:12 AMNewsfilter
Tiziana Initiates Alzheimer's Trial with First Patient Dosing Next Week
  • Trial Launch: Tiziana Life Sciences announces the commencement of its early Alzheimer's clinical trial with patient enrollment underway, expecting to dose the first patient with intranasal foralumab next week, marking a significant advancement in neuroinflammation treatment.
  • Therapeutic Innovation: The trial will evaluate intranasal foralumab both as a monotherapy and in combination with FDA-approved anti-amyloid therapy lecanemab, aiming to simultaneously target amyloid pathology and persistent microglial inflammation, potentially achieving disease modification.
  • Biomarker Support: New TSPO-PET imaging evidence reveals persistent widespread microglial activation in an Alzheimer's patient despite lecanemab treatment, underscoring the need for therapies addressing neuroinflammation and further validating foralumab's potential efficacy.
  • Strategic Implications: Tiziana's CEO Ivor Elrifi emphasizes that this trial not only explores a novel approach to Alzheimer's treatment but may also lay the groundwork for future therapeutic strategies, advancing the role of immune modulation in neurodegenerative diseases.
[object Object]
Preview
9.0
03:22 AMGlobenewswire
Tiziana Initiates Alzheimer’s Drug Trial, First Patient Dosing Next Week
  • Trial Launch: Tiziana Life Sciences has announced the commencement of its early Alzheimer’s clinical trial, with the first patient expected to be dosed next week, marking a significant advancement in the development of novel immunomodulatory therapies.
  • Therapeutic Evaluation: The trial will assess intranasal foralumab both as a monotherapy and in combination with FDA-approved anti-amyloid therapy lecanemab, aiming to simultaneously target amyloid pathology and persistent neuroinflammation, potentially achieving disease modification.
  • Imaging Evidence Support: Recent TSPO-PET imaging reveals persistent widespread microglial activation in an Alzheimer’s patient despite lecanemab treatment, underscoring the need for therapies addressing neuroinflammation and further validating the potential efficacy of foralumab.
  • Innovative Treatment Outlook: Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, designed to induce regulatory T cells to suppress pathological neuroinflammation, potentially opening new avenues for Alzheimer’s treatment.
[object Object]
Preview
7.5
12-02Globenewswire
Tiziana Plans Spinout of TZLS-501 to Enhance Strategic Focus and Shareholder Value
  • Spinout Announcement: Tiziana Life Sciences has announced plans to spin out its fully human anti-IL-6 receptor monoclonal antibody TZLS-501 into a separate publicly traded company, enhancing strategic focus and driving shareholder value.
  • Market Potential: This decision is partly driven by heightened industry interest in the IL-6 pathway, underscored by Novartis' $1.4 billion acquisition of Tourmaline Bio, highlighting the significant market potential for IL-6 therapeutics.
  • Shareholder Value: Tiziana shareholders will retain value from TZLS-501 through the distribution of shares in the new entity on the record date, ensuring their interests are preserved in the spinout.
  • Future Development: While the transaction requires shareholder approval, the company believes this move will unlock dedicated resources for the development of TZLS-501 while maintaining focus on its lead program, intranasal foralumab.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tiziana Life Sciences Ltd (TLSA) stock price today?

The current price of TLSA is 1.78 USD — it has increased 3.49 % in the last trading day.

arrow icon

What is Tiziana Life Sciences Ltd (TLSA)'s business?

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).

arrow icon

What is the price predicton of TLSA Stock?

Wall Street analysts forecast TLSA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tiziana Life Sciences Ltd (TLSA)'s revenue for the last quarter?

Tiziana Life Sciences Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Tiziana Life Sciences Ltd (TLSA)'s earnings per share (EPS) for the last quarter?

Tiziana Life Sciences Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Tiziana Life Sciences Ltd (TLSA)'s fundamentals?

The market is revising No Change the revenue expectations for Tiziana Life Sciences Ltd (TLSA) for FY2024, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.33%.
arrow icon

How many employees does Tiziana Life Sciences Ltd (TLSA). have?

Tiziana Life Sciences Ltd (TLSA) has 8 emplpoyees as of December 13 2025.

arrow icon

What is Tiziana Life Sciences Ltd (TLSA) market cap?

Today TLSA has the market capitalization of 204.38M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free